Petros Pharmaceuticals Inc. (PTPI): Price and Financial Metrics
GET POWR RATINGS... FREE!
PTPI POWR Grades
- PTPI scores best on the Value dimension, with a Value rank ahead of 77.05% of US stocks.
- The strongest trend for PTPI is in Stability, which has been heading up over the past 47 days.
- PTPI's current lowest rank is in the Momentum metric (where it is better than 9.18% of US stocks).
PTPI Stock Summary
- With a market capitalization of $10,146,932, PETROS PHARMACEUTICALS INC has a greater market value than just 2.97% of US stocks.
- With a year-over-year growth in debt of 455.1%, PETROS PHARMACEUTICALS INC's debt growth rate surpasses 96.14% of about US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PTPI comes in at -222.51% -- higher than that of merely 2.62% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to PETROS PHARMACEUTICALS INC are AYTU, EHTH, XRX, TKNO, and HAS.
- To dig deeper into the stock's financial statements, go to PTPI's page on browse-edgar?action=getcompany&CIK=0001815903.
PTPI Valuation Summary
- In comparison to the median Healthcare stock, PTPI's EV/EBIT ratio is 107.89% lower, now standing at -0.6.
- Over the past 23 months, PTPI's price/sales ratio has gone down 1.2.
Below are key valuation metrics over time for PTPI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PTPI | 2022-11-01 | 1.3 | 0.3 | -0.9 | -0.6 |
| PTPI | 2022-10-31 | 1.2 | 0.3 | -0.8 | -0.6 |
| PTPI | 2022-10-28 | 1.2 | 0.3 | -0.8 | -0.6 |
| PTPI | 2022-10-27 | 1.2 | 0.3 | -0.8 | -0.5 |
| PTPI | 2022-10-26 | 1.3 | 0.3 | -0.9 | -0.6 |
| PTPI | 2022-10-25 | 1.4 | 0.3 | -0.9 | -0.7 |
PTPI Stock Price Chart Interactive Chart >
PTPI Price/Volume Stats
| Current price | $0.43 | 52-week high | $5.20 |
| Prev. close | $0.44 | 52-week low | $0.37 |
| Day low | $0.43 | Volume | 3,700 |
| Day high | $0.47 | Avg. volume | 961,005 |
| 50-day MA | $0.47 | Dividend yield | N/A |
| 200-day MA | $0.87 | Market Cap | 8.95M |
Petros Pharmaceuticals Inc. (PTPI) Company Bio
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.
Latest PTPI News From Around the Web
Below are the latest news stories about PETROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PTPI as an investment opportunity.
Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate UpdatePetros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced financial results for the third quarter ended September 30, 2022. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayPre-market stock movers continue to be a major topic as we dive into the latest news investors need to know about on Friday! |
What will the future hold for Petros Pharmaceuticals Inc. (NASDAQ:PTPI) stock?Petros Pharmaceuticals Inc. (PTPI)’s stock is trading at $0.48 at the moment marking a rise of 25.66% from the last session close. As of this writing, shares are priced at -90.79% less than their 52-week high of $5.20, and 29.43% over their 52-week low of $0.37. Based on the past 30-day period, the stock price […] |
Petros Pharma stock jumps ~22% after erectile dysfunction drug gets label expansionPetros Pharmaceuticals (PTPI) on Tuesday said the U.S. FDA labeling for its erectile dysfunction ((ED)) drug Stendra had been expanded |
New FDA-Approved Labeling for Petros Pharmaceuticals’ STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical ProstatectomyExpanded STENDRA Labeling Now Includes Data on a Significant Population of Men Not Previously Included Following Submission of Additional Clinical Trial DataNEW YORK, NY / ACCESSWIRE / October 25, 2022 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a … |
PTPI Price Returns
| 1-mo | -10.36% |
| 3-mo | -37.72% |
| 6-mo | -55.89% |
| 1-year | -79.43% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -87.09% |
| 2021 | -24.32% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...